JPM 2024: Pharma CEOs face a crossroads
from The Refill, by MM+M Hosted by Jack O'Brien, Lecia Bushak, Marc Iskowitz, Michelle Chen
With the 2024 J.P. Morgan Healthcare Conference underway, MM+M’s Marc Iskowitz provides an update from on the ground in San Francisco. Digital Editor Jack O’Brien talks with Insilico Medicine President Michelle Chen about the company’s ongoing work to bring generative AI’s capabilities to the world of clinical research. Senior Reporter Lecia Bushak talks about the Food and Drug Administration’s historic move to give Florida the ability to import medications from Canada at much lower prices than in the U.S. Eli Lilly’s LillyDirect website launch marks a direct-to-consumer push for GLP-1 drugs like Zepbound, we dive into Defense Secretary Lloyd Austin’s controversial prostate cancer treatment saga and examine the brands and influencers toasting to Dry January. Is your team still treating AI like a side experiment while competitors use it to win? Cut through the buzzword fatigue. On November 12th, join hundreds of top marketers in New York City for AI Deciphered, presented by Campaign, MM+M, and PRWeek. Get real-world playbooks from leaders like Reddit’s Rob Gaige and Yahoo’s Matt Sanchez across dedicated tracks built for daily execution. Check us out at: mmm-online.com Follow us: YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Embed this episode
What this episode covers
The 2024 J.P. Morgan Healthcare Conference is underway and Marc Iskowitz provides an update from on the ground in San Francisco. Jack O’Brien talks with Insilico Medicine President Michelle Chen about the company’s ongoing work to bring generative AI’s capabilities to the world of clinical research. Finally, Defense Secretary Lloyd Austin’s controversial prostate cancer treatment saga tops the Trends segment.
No transcript yet.